Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - piletina - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Europska Unija - hrvatski - EMA (European Medicines Agency)

intervet international b.v. - cellular " potpomognuta živa рекомбинантная turske герпесвирус (soj hvp360), izražavajući sintezu proteina virusa nd i vp2 s proteinima virusa ИБД - ptica virus herpesa (bolest Марека) + ptičji virus infektivne бурсальной bolesti (bolest Гамборо) + virusa ньюкаслской bolesti/парамиксовируса - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekcije respiratornih sincicijskih virusa - cjepiva - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infekcije respiratornih sincicijskih virusa - cjepiva - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. pogledajte odjeljke 4. 2 i 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

intervet international bv - cjepivo protiv virusa bolesti plavog jezika, serotip 8 (inaktiviran) - Инактивированные virusnih cjepiva, virus блютанга, ovce - sheep; cattle - cattle to stimulate active immunity in sheep from 6 weeks of age against bluetongue virus serotype 8 to reduce viraemia sheep to stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia,.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - imunološki za aves - piletina - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).

Europska Unija - hrvatski - EMA (European Medicines Agency)

merck sharp & dohme b.v. - virus varicella-zoster (živ, atenuiran) - herpes zoster; immunization - virusna cjepiva - zostavax je indiciran za prevenciju herpes zoster ("zoster" ili šindre) i post-herpetičke neuralgije povezane s herpes zosterom. zostavax prikazana je za cijepljenje osoba u dobi od 50 i više godina.

Europska Unija - hrvatski - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - živjeti panleucopenia virus mačke / парвовирусный + video mačke, virus ринотрахеита + video mačji калицивирус + инактивированный virus leukemije mačaka - mačke - za aktivnu imunizaciju mačaka od osam tjedana protiv: mačji kalicivirozu kako bi se smanjili klinički znakovi. mačji virusni ринотрахеит za smanjenje kliničkih znakova i izlučivanje virusa. mačke panleucopenije kako bi se spriječila leukopenija i smanjili klinički znakovi. mačje leukemije kako bi se spriječila uporna viremija i klinički znakovi povezane bolesti. početak imuniteta: 3 tjedna nakon primarne cijepljenja za komponente panleucopenije i leukemije i 4 tjedna nakon primarne cijepljenja za virusne komponente kalicivirusnih i rinotraheitisa. trajanje imuniteta: jedna godina nakon primarne cijepljenja za sve sastojke.

Europska Unija - hrvatski - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - cjepiva - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa - inaktivirani virus zapadnoga nila, soj vm-2 - imunološke za kopitare - konji - za aktivnu imunizaciju konja od šest mjeseci ili stariji protiv bolesti zapadnog nila virusom smanjenjem broja konjskih virusa.